Evidence Table J2. CONTINUOUS outcomes for class ANTI-BACTERIAL (ORAL)/RETINOID (TOPICAL)

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	J.01.03			**Tretinoin + emollient + tetracycline**		**Tetracycline + sulfur/salicylic acid + polyethyle**		
323 ↑ N=122 Parallel Mild/mod/sev		**Comedones change (%)** Between P-value: Tret/Tet vs Tret/BP .05 ; Tret/BP vs Tet/Sul NS.	Short (4)	Percent change: -25		Percent change: -3		
		Papules+pustules change (%) Between P-value: Tret/Tet vs Tret/BP NS ; Tret/BP vs Tet/Sul NS.	Short (4)	Percent change: -42		Percent change: -40		
		Total lesions change (%) Between P-value: Tret/Tet vs Tret/BP .05 ; Tret/BP vs Tet/Sul NS.	Short (4)	Percent change: -30 (30.)		Percent change: -15 (40.)		
		Comedones change (%)	Mid (12)	Percent change: -63		Percent change: -40		
		Comedones change (%) Between P-value: Tret/Tet vs Tret/BP .001 ; Tret/BP vs Tet/Sul NS.	Mid (12)	Percent change: -65		Percent change: -40		
		Inflammatory change (%) Between P-value: Tret/Tet vs Tret/BP .05 ; Tret/BP vs Tet/Sul .05.	Mid (12)	Percent change: -75		Percent change: -50		
		Total lesions change (%) Between P-value: Tret/Tet vs Tret/BP .01 ; Tret/BP vs Tet/Sul NS.	Mid (12)	Percent change: -68 (30.)		Percent change: -45 (40.)		
		Dryness Between P-value: Tret/Tet vs Tret/BP .001 ; Tret/BP vs Tet/Sul NS.	Long (16	Measure: 0		Measure: 1		
		Erythema Between P-value: Tret/Tet vs Tret/BP NS ; Tret/BP vs Tet/Sul NS.	Long (16	Measure: 0		Measure: 0		
		Inflammatory change (%) Between P-value: Tret/Tet vs Tret/BP .05 ; Tret/BP vs Tet/Sul NS.	Long (16	Percent change: -75		Percent change: -53		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
323 ↑ Parallel	N=122 Mild/mod/sev	**Oiliness** Between P-value: Tret/Tet vs Tret/BP NS ; Tret/BP vs Tet/Sul NS.	Long (16	Measure: 0		Measure: 0		
		Peeling	Long (16	Measure: 0		Measure: 1		
		Total lesions change (%) Between P-value: Tret/Tet vs Tret/BP .001 ; Tret/BP vs Tet/Sul NS.	Long (16	Percent change: -70 (40.)		Percent change: -45 (40.)		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.